Abstract The Oxford Classic Epithelial-Mesenchymal Transition (OxC-EMT) score identifies a high-risk subgroup of High-Grade Serous Carcinoma (HGSC) patients with inferior survival. This commentary discusses the evaluation of HGSC biomarkers in context and the important steps in transition from a prognostic to a validated predictive biomarker to inform clinical utility.